Incannex Healthcare announced first patient dosing in the DReAMzz Phase 2 dose-optimization study of IHL-42X, its oral fixed-dose combination candidate for treating obstructive sleep apnea. The milestone follows positive Phase 2 RePOSA results showing AHI reductions up to 83% and FDA Fast Track designation. The DReAMzz...
Incannex Healthcare received A$6.0 million in R&D tax incentive refunds from the Australian Government with an additional A$5.1 million expected later in 2026, totaling over A$11.1 million in non-dilutive capital. The company plans to use these proceeds to advance clinical programs including IHL-42X and PSX-001, while...
Incannex Healthcare Inc. (Nasdaq: IXHL) has been recognized as the winner of the 'Best New Technology Solution for Drug Development' at the 10th annual MedTech Breakthrough Awards for its lead drug candidate IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea. The Phase 2 RePOSA trial...
Incannex Healthcare announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for obstructive sleep apnea (OSA), following statistically significant Phase 2 results. The company received FDA Fast Track Designation and plans to conduct a Phase 2 crossover dose-optimization study...
Incannex Healthcare Inc. (Nasdaq: IXHL) announced the appointment of three distinguished members to its Clinical Advisory Board: Murray B. Stein, MD, MPH from UCSD; Andrew Cutler, MD from SUNY Upstate Medical University; and Amir Kalali, MD. The CAB will provide clinical and scientific guidance as PSX-001, an oral...
Several biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.
NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in...
MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S....
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. Bumble reported quarterly losses of 19 cents per share which missed the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $273.64 million which missed the analyst...
MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S....
Highlights:
MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is pleased to announce that patient...
Highlights:
MELBOURNE, Australia and NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that an independent Institutional...
U.S. stocks traded mixed, with the Nasdaq Composite falling around 0.3% on Friday. Shares of Global Mofy Metaverse Limited (NASDAQ: GMM) shares fell sharply during Friday’s session after the company announced a $10 million follow-on offering. Global Mofy Metaverse shares dipped 37.2% to $7.00 on Friday. Here are some...
Highlights:
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results. Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion (+2% organically), missing the consensus of $7.09 billion. Adjusted EPS of $1.05 (+6% Y/Y)...
MELBOURNE, Australia and NEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is pleased to provide the...
U.S. stock futures traded higher this morning, with the Dow Jones futures gaining round 0.1% on Wednesday. Shares of Box, Inc. (NYSE: BOX) fell sharply in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 guidance below estimates. The company said revenue...
U.S. stock futures traded lower this morning, with the Dow Jones futures falling more than 40 points on Monday. Shares of Merit Medical Systems, Inc. (NASDAQ: MMSI) shares fell in pre-market trading after the company reported a proposed private placement of $550 million of convertible senior notes. Merit Medical...
Headlines via Polygon.io. Links open the original publisher.